Sarah Geers represents pharmaceutical clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the Patent Trial and Appeal Board (PTAB). Her practice spans Hatch-Waxman and other patent infringement actions, inter partes review proceedings, trade secret, and misappropriation actions. Her litigation experience spans discovery, trial, and appeal.
Sarah was involved in the successful resolution of Hatch-Waxman litigation involving the transdermal patch Butrans®, as well as a plethora of patent infringement actions involving the pain medication OxyContin®. More recently, she was part of a team that helped Juno Therapeutics and Sloan Kettering win a more than $1.1 billion final award in a case in which the jury found that defendant Kite Pharma willfully infringed the asserted patent for cancer immunotherapy. She currently represents Merck in patent infringement actions against 16 generic defendants groups related to Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.
Sarah is currently an adjunct professor at Seton Hall University School of Law, where she teaches a course on patent litigation.
Sarah was named a Law360 Life Sciences Rising Star in 2020, which is awarded to lawyers under 40 whose legal accomplishments belie their age.
Before becoming a lawyer, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research.
Didn’t Cut the Mustard: PTAB Finds Claims Lacked Written Description and Enablement, PTAB Litigation Blog
- Seton Hall University (J.D. summa cum laude 2010; Order of the Coif; Comments Editor, Law Review); University of Minnesota (B.S. in Chemistry with high distinction and B.A. in Spanish Studies with high distinction 2003; Tau Beta Pi)
- New York, New Jersey, and registered to practice before the U.S. Patent and Trademark Office
- Conversational Spanish